Drug intelligence / Profile preview

GLSE compound

Development stage: Unknown
Lead developer: Chinese PLA General Hospital
Administration: Oral

Overview

GLSE compound is a nutraceutical intervention derived from the spores of *Ganoderma lucidum* (commonly known as Lingzhi or Reishi mushroom). It is being evaluated by the Chinese PLA General Hospital as a supportive clinical nutrition therapy for patients with lung neoplasms and breast carcinoma who are undergoing radiation and chemotherapy. The extract is believed to possess immunomodulatory and anti-tumor properties, potentially enhancing the host's immune response by activating natural killer (NK) cells and T-lymphocytes, and reducing the adverse effects associated with conventional oncological treatments.

Other names: Ganoderma lucidum spore extractLingzhi spore extractReishi mushroom spore extract

Targets

TLR4 (Toll-like receptor 4)

Beyond the preview

Go deeper on GLSE compound.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLSE compound.

Explore the full profile